Cyclo Therapeutics Earnings Estimate

CYTH Stock  USD 0.78  0.01  1.27%   
By analyzing Cyclo Therapeutics' earnings estimates, investors can diagnose different trends across Cyclo Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Cyclo Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Cyclo Therapeutics is projected to generate 0.0 in earnings per share on the 31st of December 2024. Cyclo Therapeutics earnings estimates show analyst consensus about projected Cyclo Therapeutics EPS (Earning Per Share). It derives the highest and the lowest estimates based on Cyclo Therapeutics' historical volatility. Many public companies, such as Cyclo Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Cyclo Therapeutics' earnings estimates, investors can diagnose different trends across Cyclo Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. The current Gross Profit is estimated to decrease to about 709.2 K. The Cyclo Therapeutics' current Pretax Profit Margin is estimated to increase to -20.36
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Cyclo Therapeutics Earnings per Share Projection vs Actual

About Cyclo Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Cyclo Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Cyclo Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Cyclo Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-75.5 M-71.7 M
Earnings Yield(0.89)(0.84)
Price Earnings Ratio(1.49)(1.56)
Price Earnings To Growth Ratio 0.04  0.03 

Currently Active Assets on Macroaxis

When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.90)
Revenue Per Share
0.046
Quarterly Revenue Growth
0.051
Return On Assets
(2.82)
Return On Equity
(226.64)
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.